GlassScriptPhysician profile
Randy C Roth
NPI 1013068212
$6,086.36
in general payments reported to CMS, 2019-2025
32 companies · $433 in 2025
The $433 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,599 · 2020: $248 · 2021: $498 · 2022: $343 · 2023: $262 · 2024: $703 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,398.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $3,065.20 | 2019-2024 | Yupelri |
| Pfizer INC. | $419.62 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $343.95 | 2019-2025 | Eliquis, Camzyos |
| Lexicon Pharmaceuticals, INC. | $339.11 | 2024 | Inpefa |
| Novartis Pharmaceuticals Corporation | $242.40 | 2019-2025 | |
| Abbvie INC. | $238.33 | 2021-2025 | Teflaro |
| Vifor Pharma, INC. | $235.43 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $154.61 | 2021-2025 | Ultomiris |
| Janssen Pharmaceuticals, INC | $153.32 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $145.80 | 2023 | Xarelto |
| Csl Behring | $78.17 | 2020-2024 | Kcentra |
| Intuitive Surgical, INC. | $68.49 | 2024 | |
| Melinta Therapeutics, LLC | $66.33 | 2022-2025 | Rezzayo, Kimyrsa |
| Boston Scientific Corporation | $56.86 | 2025 | Watchman Access System |
| Portola Pharmaceuticals, LLC | $55.38 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $51.51 | 2019-2021 | |
| Nabriva Therapeutics, Plc | $47.28 | 2020 | |
| Allergan, INC. | $39.69 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $35.64 | 2024 | Uptravi |
| Viatris Specialty LLC | $34.28 | 2025 | Yupelri |
| Mallinckrodt Hospital Products INC. | $23.14 | 2024 | Terlivaz |
| Biofire Diagnostics, LLC | $22.20 | 2019 | |
| Averitas Pharma INC. | $21.07 | 2023 | Qutenza |
| Kiniksa Pharmaceuticals International, Plc | $21.04 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.01 | 2022 | |
| Abbott Laboratories | $20.15 | 2024 | Diamondback Coronary |
| Paratek Pharmaceuticals, INC. | $17.00 | 2019 | |
| Avanir Pharmaceuticals, INC. | $14.79 | 2019 | |
| Gilead Sciences, INC. | $14.62 | 2021 | |
| Amgen INC. | $13.97 | 2019 | |
| Ethicon US, LLC | $13.45 | 2024 | N/A |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Roth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.